Bayer Pharma Aktiengesellschaft

Piramal Imaging Sa

Bayer Aktiengesellschaft

Dana-farber-cancer Institute Inc.

The Broad Institute, Inc.

A.n. Nesmeyanov Institute of Organoelement Compounds the Russian Academy of Sciences

N. P. Bechtereva Institute of the Human Brain of the Russian Academy of Sciences

A. N. Nesmeyanov Institute of Organoelement Compounds, the Russian Academy of Science (ineos Ras)

Institute of the Human Brain, Russian Academy of Science (ihb Ras)

Keith Graham

Ulrich Klar

Philip Lienau

Gerhard Siemeister

Hans Briem

Detlev Sülzle

Georg Kettschau

Knut Eis

Volker Schulze

Ursula Mönning

Mathias Berndt

Lutz Lehmann

Ulf Bömer

Heribert Schmitt-Willich

Thomas Brumby

Kirstin Petersen

Lars Wortmann

Timo Stellfeld

Florian Puehler

Matthias Friebe

Ludger Dinkelborg

René Tempel

Jozsef Bálint

Dirk Kosemund

Lars Bärfacker

Markus Berger

Matthew Meyerson

Antje Margret Wengner

Helmut Sonnenschein

Martin Kruger

Wilhelm Bone

Andrea Hägebarth

Simon Holton

Simon Mensah Ametamey

Holger Siebeneicher

Marion Hitchcock

Heidi Greulich

Heinz Graubaum

Stephan Siegel

Julien Lefranc

Jorma Haβfeld

Dieter Moosmayer

Jens Schröder

Nicole Schmidt

Franziska Siegel

Andre Müller

József Bálint

Daniel Korr

Uwe Eberspächer

Yuri Belokon

Norman Koglin

Anja Giese

Bethany Kaplan

Simon Ametamey

Hassan Youssef Harb

Phi Manh Dinh

Nikolaevna Raisa Krasikowa

Fedorovna Olga Kuznetsova

Matthias Berndt

Ananth Srinivasan

Detlef Suelzle

Mylene Tania Karramkam

Raisa Nikolaevna Krasikowa

Olga Fedorovna Kuznetsova

Eis Knut

Lars BÄRFACKER

Mylène Karramkam

Florian Pühler

Compounds of formula (I) processes for their production and their use as pharmaceuticals. 

4H-pyrrolo[3,2-c]pyridin-4-one derivatives

The present invention relates to substituted pyrazolopyridinamine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, inflammatory disease and disease associated with inflammatory pain, as a sole agent or in combination with other active ingredients.

Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors

Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals. 

3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones

Compound of formula (I), processes for their production and their use as pharmaceuticals. 

4H-pyrrolo[3,2-C]pyridin-4-one derivatives

Compounds of formula (I) as described herein, processes for their production and their use as pharmaceuticals. 

1H-pyrrol-3-amines

Compounds of formula (I) as described herein processes for their production and their use as anti-cancer agents. 

The present invention relates to substituted thiazolopyrimidine compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

Substituted thiazolopyrimidines

The present invention relates to substituted thienopyrimidine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Thienopyrimidines

The compounds and the synthesis of [F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamate, their derivatives as set forth in formula (I) and their uses are described.

[F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamine, derivatives thereof and use thereof and processes for their preparation

What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use.

[F-18]-labelled L-glutamic acid and L-glutamine derivatives (I), their use and processes for their preparation

This invention relates to novel compounds suitable for labeling byF and to the correspondingF labeled compounds themselves,F-fluorinated analogs thereof and their use as reference standards, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by Positron Emission Tomography (PET).

Radiolabeled amino acids for diagnostic imaging

The invention relates to a process for the production of radiotracers. In particular, this invention relates the isolation of radiotracers with containers filled with a stationary phase.

Usage of low to medium-pressure liquid chromatography for the purification of radiotracers

The present invention relates to novel compounds suitable for or already radiolabeled withF, methods of making such compounds and use of such compounds for diagnostic imaging. Such labeled compounds are characterized by Formula II, wherein the substituents G, Q, L, Y and U have the meaning as defined in the specification and claims. 

[object Object]

Growing community of inventors

Berlin, Germany

Keith Graham